Why did Racura Oncology (ASX:RAC) raise $34.3 million?

Racura Oncology (ASX:RAC) raised the $34.3 million to fully fund three upcoming clinical trials for its RC220 programme. The company stated that the secured capital provides a strong cash balance to advance its clinical pipeline.

What are the total financial figures raised by Racura Oncology (ASX:RAC)?

Racura Oncology (ASX:RAC) secured a total of $34.3 million through multiple fundraising initiatives spanning from June 2024 to June 2026. This total includes a final contribution of $636,506.25 from a recent option underwriting agreement.

What does the shortfall option placement mean for Racura Oncology (ASX:RAC) shareholders?

Racura Oncology (ASX:RAC) partially placed 509,205 shortfall options specifically to limit shareholder dilution. The company confirmed this decision restricted the placement from a total available shortfall of 631,201 options while still bringing in additional cash.

What are the clinical trials being funded by Racura Oncology (ASX:RAC)?

Racura Oncology (ASX:RAC) is funding clinical trials targeting acute myeloid leukaemia and Epidermal Growth Factor Receptor mutant non-small cell lung cancer. The company also plans to evaluate chemotherapy-related cardioprotection in solid tumour patients.

How is the Racura Oncology (ASX:RAC) fundraising structured to avoid transaction fees?

Racura Oncology (ASX:RAC) structured its capital raisings through direct bonus options, piggyback option conversions, and private placements with shareholders. Consequently, the company reported that no broker or underwriter fees were paid during these capital raisings.

Image for illustrative purposes only. Not a real photo.

Racura Oncology raises $34.3M for clinical trials

Written by Brie CarterPublished Jun 16, 2026, 4:26 AM

Racura Oncology has secured a total of $34.3 million through multiple fundraising initiatives.
The capital was raised directly from shareholders without paying any broker or underwriter fees.
The company will use the funds to fully finance three oncology clinical programmes.

Racura Oncology (ASX:RAC) has raised $34.3 million to fully fund three upcoming clinical trials.

The multi-year fundraising programme has strengthened the company's cash balance compared to previous years.

“We look forward to updating investors on RC220's clinical progress,” said Racura Managing Director Dr Daniel Tillett.

The company placed 509,205 shortfall options to limit shareholder dilution, contributing an additional $636,506.25.

Following the announcement, the Racura share price was unchanged at $2.35.

The funds will support trials in acute myeloid leukaemia and non-small cell lung cancer.

Racura also plans to evaluate chemotherapy-related cardioprotection in solid tumour patients.

Racura Oncology raises $34.3M for clinical trials

Frequently asked questions

Assets related to this article